bioMerieux (OTCMKTS:BMXMF) Upgraded at Zacks Research

Posted by Brenda Bartman on Sep 30th, 2026

bioMerieux (OTCMKTS:BMXMF – Get Free Report) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday, Zacks reports.

BMXMF has been the topic of several other reports. Morgan Stanley reaffirmed an “underweight” rating on shares of bioMerieux in a report on Friday, September 11th. Piper Sandler initiated coverage on bioMerieux in a research report on Thursday, June 11th. They issued a “neutral” rating on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a research note on Wednesday, June 17th. Finally, UBS Group lowered shares of bioMerieux from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Five equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce”.

View Our Latest Stock Analysis on BMXMF

bioMerieux Stock Performance

OTCMKTS BMXMF opened at $83.27 on Monday. The stock has a 50-day simple moving average of $82.98 and a two-hundred day simple moving average of $87.89. bioMerieux has a fifty-two week low of $77.00 and a fifty-two week high of $138.15. The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08.

bioMerieux Company Profile

(Get Free Report)

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.